1 |
Drawing on therapy developed to save soldiers, an app aims to prevent suicide in those at highest risk |
2 |
Genomics is racing toward a $100 genome. Are we ready for it? |
3 |
The Morris ALS Principles: A model for empowering all disease communities |
4 |
Exclusive analysis of biotech, pharma, and the life sciences |
5 |
Start your free trial! |
6 |
The 41 best books and podcasts on health and science to check out this summer |
7 |
Health care’s high rollers: As the pandemic raged, CEOs’ earnings surged |
8 |
From social media to pink billboards, it’s suddenly ‘hot’ to discuss gut diseases |
9 |
In the label ‘adult failure to thrive,’ medicine reveals its own failures |
10 |
This clinical trial wanted to end breast cancer disparities. But first it needed to enroll Black women |
11 |
Cue Health rode Covid-19 to an NBA deal and a $3 billion valuation. Now it faces layoffs and a rocky future |
12 |
Biotech is practically in San Diego’s DNA. Here’s how it got there — and how it might evolve |
13 |
‘It was stolen from me’: Black doctors are forced out of training programs at far higher rates than white residents |
14 |
Listen: Well-paid CEOs, behind the scenes at Moderna, & Biogen’s CEO search |
15 |
Listen: The double standard of discipline between nurses and physicians |
16 |
Listen: CRISPR for the heart, biotech’s recovery, & what it means to be a ‘hot girl’ |
17 |
Listen: Vertus Hardiman and the medical tragedies that must not be forgotten |
18 |
American Cancer Society’s VC arm partners with Third Rock on oncology companies |
19 |
Encouraged by right-wing doctor groups, desperate patients turn to ivermectin for long Covid |
20 |
‘A scary time’: Fear of prosecution forces doctors to choose between protecting themselves or their patients |
21 |
As new variant spreads, a crucial drug to protect the most vulnerable goes vastly underused |
22 |
Beyond a CRISPR treatment’s encouraging results, some scientists see a need for more data on risk |
23 |
App & Other Products |
24 |
Group Subscriptions |